# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FDA notified Applied Therapeutics that it required additional time to review supplemental analyses of previously submitted ...
RBC Capital analyst Brian Abrahams initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating and ann...
-SEC Filing
UBS analyst Esther Rajavelu maintains Applied Therapeutics (NASDAQ:APLT) with a Buy and raises the price target from $12 to ...
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.
UBS analyst Esther Rajavelu maintains Applied Therapeutics (NASDAQ:APLT) with a Buy and raises the price target from $4 to $12.
Applied Therapeutics (NASDAQ:APLT) reported quarterly losses of $(1.42) per share which beat the analyst consensus estimate of ...